| Peer-Reviewed

Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir

Received: 20 March 2023     Accepted: 10 April 2023     Published: 10 May 2023
Views:       Downloads:
Abstract

Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.

Published in International Journal of Clinical and Experimental Medical Sciences (Volume 9, Issue 2)
DOI 10.11648/j.ijcems.20230902.12
Page(s) 25-28
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Chronic Hepatitis B, Tenofovir, HBV-DNA, Transaminases, Patients, Chad

References
[1] World Health Organization, Global Hepatitis Programme. Global hepatitis report, 2017 [Internet]. Geneva, Switzerland: World Health Organization; 2017.
[2] Paccoud O, Surgers L, Lacombe K. Infection par le virus de l’Hépatite B: histoire naturelle, manifestations cliniques et principes thérapeutiques. Revue de médecine interne. [Hepatitis B virus infection: natural history, clinical manifestations and therapeutic principles. Journal of Internal Medicine.]. 2019; 40: 590-98.
[3] Rapport sur l’Hépatite B et C au Canada: 2018 [Report on Hepatitis B and C in Canada: 2018].
[4] Lahlali M, Abid H, Lamine A, Lahmidani N, El Yousfi M, Benajah D et al. Epidémiologie des hépatites virales dans le Grand Maghreb. La Tunisie Médicale. [Epidemiology of viral hepatitis in the Greater Maghreb. Medical Tunisia]. 2018; 96 (10-11): 606-19.
[5] Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBs Ag seroprevalence and endemicity. Vaccine. 2012; 30 (12): 2212–19.
[6] Salamata D, Marie LB, Mamadou NG, Mame AT, Daouda D, Mouhamadou M et al. Hépatite virale B: aspects cliniques, paracliniques et évolutifs dans le service d’Hépato Gastroentérologie de l’Hôpital Aristide Le Dantec: à propos de 728 cas. [Viral hepatitis B: clinical, paraclinical and evolutionary aspects in the Hepato Gastroenterology department of the Aristide Le Dantec Hospital: about 728 cases]. Pan African Medical Journal. 2018; 31: 1-7.
[7] Katilé D, Konaté I, Goita D, Kaboré M, Dicko MY, Mallé O, et al. Prevalence of HBs Antigen and serological profile of Hepatitis B virus in General Medicine Consultation at the Regional Hospital of Kayes in Mali. Health Sci. Dis. October - November - December 2018; Vol 19 (4): 16-19.
[8] Bessimbaye N, Moussa AM, Mbanga D, Tidjani A, Mahamat SO, Nahor Ngawara M et al. Seroprevalence of HBsAg and Anti-HCV antibody in HIV1 infected persons in N'Djaména, Chad. Bull Soc Pathol Exot; (2014) 107: 327-31.
[9] Moussa AM, Habkreo M, Chatté A, Bordé E, Fouda AA. Nadlaou B. Frequency of Viral Replication Markers in Chronic HBV Carriers in N'Djamena, Chad. Open Journal of Gastroenterology. 2022; 12: 271-77.
[10] Touré PS, Berthé A, Diop MM, Diarra AS, Lo G, Sow-Sall A, et al. Non-invasive markers in the evaluation of liver fibrosis in Senegalese chronic hepatitis B virus carriers: about 404 cases. RAFMI 2017; 4 (2): 30-34.
[11] Gueye MN, Sarr B, Diallo S, Diouf G, Daouda D, Thioubou MA, et al. Assessment of the state of knowledge on viral hepatitis B of patients in Hepato-Gastroenterology consultation at the General Idrissa Pouye Hospital. OSR Journal of Dental and Medical Sciences. 2020 Jun, 19: 53-57.
[12] Guangqin X, Jiayin Y, Lunan Y. Comparison of Diagnostic Accuracy of Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Adult Patients with Chronic Hepatitis B Virus Infection: A Systemic Review and Meta-analysis, American Association for the Study of Liver Diseases. 24 Nov 2014, 61 (1): 292-302.
[13] INSEED. Enquête Démographique et de sante et à indicateurs Multiples au Tchad (EDS-MICS). [Demographic and Health Survey and Multiple Indicators in Chad (EDS-MICS)]. 2014-2015. 2016.
[14] Jerome G and the working group. "Biological markers of hepatic fibrosis. Non-invasive assessment of liver fibrosis during chronic viral hepatitis C. Presse Med. 2006; 35: 1317-26.
[15] World Health Organization. Guidelines for prevention, care and treatment for people with chronic hepatitis B infection April 2016.
[16] Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges.
[17] Sombié R, Sangaré L, Guingané A, Tiendrébéogo A, Kaboré D, Bougouma A. Treatment of chronic hepatitis B with nucleos(t)ides analogues. J Afr Hepato-Gastroenterology. sept 2015; 9 (3): 114-8.
[18] Sombié R, Bougouma A, Diallo O, Bonkoungou G, Cissé R, Sangare L et al. Chronic hepatitis B: epidemiological, diagnostic, therapeutic, and evolutionary aspects at the Centre Hospitalier Universitaire Yalgado Ouédraogo de Ouagadougou. J Afr Hepato Gastroenterology. Jan 2010; 4 (1): 3-10.
Cite This Article
  • APA Style

    Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. (2023). Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. International Journal of Clinical and Experimental Medical Sciences, 9(2), 25-28. https://doi.org/10.11648/j.ijcems.20230902.12

    Copy | Download

    ACS Style

    Mayanna Habktéo; Ali Mahamat Moussa; Djerabet Franckly; Eiba Tamam; Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int. J. Clin. Exp. Med. Sci. 2023, 9(2), 25-28. doi: 10.11648/j.ijcems.20230902.12

    Copy | Download

    AMA Style

    Mayanna Habktéo, Ali Mahamat Moussa, Djerabet Franckly, Eiba Tamam, Tahir Mahamat Saleh, et al. Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir. Int J Clin Exp Med Sci. 2023;9(2):25-28. doi: 10.11648/j.ijcems.20230902.12

    Copy | Download

  • @article{10.11648/j.ijcems.20230902.12,
      author = {Mayanna Habktéo and Ali Mahamat Moussa and Djerabet Franckly and Eiba Tamam and Tahir Mahamat Saleh and Mairé Dehainssala},
      title = {Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir},
      journal = {International Journal of Clinical and Experimental Medical Sciences},
      volume = {9},
      number = {2},
      pages = {25-28},
      doi = {10.11648/j.ijcems.20230902.12},
      url = {https://doi.org/10.11648/j.ijcems.20230902.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20230902.12},
      abstract = {Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Clinico-Biological Evaluation of Patients with Chronic Viral Hepatitis B on Tenofovir
    AU  - Mayanna Habktéo
    AU  - Ali Mahamat Moussa
    AU  - Djerabet Franckly
    AU  - Eiba Tamam
    AU  - Tahir Mahamat Saleh
    AU  - Mairé Dehainssala
    Y1  - 2023/05/10
    PY  - 2023
    N1  - https://doi.org/10.11648/j.ijcems.20230902.12
    DO  - 10.11648/j.ijcems.20230902.12
    T2  - International Journal of Clinical and Experimental Medical Sciences
    JF  - International Journal of Clinical and Experimental Medical Sciences
    JO  - International Journal of Clinical and Experimental Medical Sciences
    SP  - 25
    EP  - 28
    PB  - Science Publishing Group
    SN  - 2469-8032
    UR  - https://doi.org/10.11648/j.ijcems.20230902.12
    AB  - Introduction: Viral hepatitis B is a major public health problem worldwide. The aim of this study was to evaluate the clinico-biological parameters in patients with chronic hepatitis B on Tenofovir. Patients and method: This was a cross-sectional study with retrospective data collection from April 1, 2019 to March 31, 2021, i.e. two years. Patients aged at least 15 years, regardless of sex, with a complete follow-up file were included. Results: A total of 920 files were evaluated, of which 145 met the inclusion criteria, i.e. a frequency of 15.76%. A male predominance was found (sex ratio 2.62). The average age was 33.24 years with extremes of 17 and 63 years. Students were more represented (36.6%). Incidental discovery was the most frequent mode (29.7%). Asthenia was the most frequent clinical manifestation (28.27%). Cytolysis was found in 82.76% of cases at the start of treatment. Creatinine levels were normal in most cases. HBV DNA was > 2000 IU/ml in 92.41% of cases. Abdominal ultrasound was normal in 51.25% of cases. Biological fibrosis scores (APRI and FIB-4) were used in almost one third of patients. The evolution was marked by a virological response of 82.35% at the 12th month and a normalization of transaminases in 91.6% of cases. Conclusion: Viral hepatitis B, a public health problem, is frequent among young people in our context. Tenofovir, effective, allows to obtain a significant virological response and a normalization of transaminases.
    VL  - 9
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad

  • Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad

  • Department of Medicine of the Chad-China Friendship Hospital, N'Djamena, Chad

  • Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad

  • Internal Medicine Department of the Centre Hospitalier Universitaire la Renaissance, N'Djamena, Chad

  • Gastroenterology/Internal Medicine Department of the University Hospital Center la Référence Nationale, N'Djamena, Chad

  • Sections